214 related articles for article (PubMed ID: 22087278)
1. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
[TBL] [Abstract][Full Text] [Related]
3. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
[TBL] [Abstract][Full Text] [Related]
4. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
[TBL] [Abstract][Full Text] [Related]
5. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
[TBL] [Abstract][Full Text] [Related]
6. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
[TBL] [Abstract][Full Text] [Related]
7. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion.
Tanaka H; Yoshida S; Oshima H; Minoura H; Negoro K; Yamazaki T; Sakuda S; Iwasaki F; Matsui T; Shibasaki M
J Pharmacol Exp Ther; 2013 Sep; 346(3):443-52. PubMed ID: 23853170
[TBL] [Abstract][Full Text] [Related]
8. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
[TBL] [Abstract][Full Text] [Related]
9. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat.
Doshi LS; Brahma MK; Sayyed SG; Dixit AV; Chandak PG; Pamidiboina V; Motiwala HF; Sharma SD; Nemmani KV
Metabolism; 2009 Mar; 58(3):333-43. PubMed ID: 19217448
[TBL] [Abstract][Full Text] [Related]
10. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
[TBL] [Abstract][Full Text] [Related]
11. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G
Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723
[TBL] [Abstract][Full Text] [Related]
12. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
[TBL] [Abstract][Full Text] [Related]
13. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
[TBL] [Abstract][Full Text] [Related]
14. AMG 837: a potent, orally bioavailable GPR40 agonist.
Houze JB; Zhu L; Sun Y; Akerman M; Qiu W; Zhang AJ; Sharma R; Schmitt M; Wang Y; Liu J; Liu J; Medina JC; Reagan JD; Luo J; Tonn G; Zhang J; Lu JY; Chen M; Lopez E; Nguyen K; Yang L; Tang L; Tian H; Shuttleworth SJ; Lin DC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1267-70. PubMed ID: 22217876
[TBL] [Abstract][Full Text] [Related]
15. In vitro and mouse in vivo characterization of the potent free fatty acid 1 receptor agonist TUG-469.
Urban C; Hamacher A; Partke HJ; Roden M; Schinner S; Christiansen E; Due-Hansen ME; Ulven T; Gohlke H; Kassack MU
Naunyn Schmiedebergs Arch Pharmacol; 2013 Dec; 386(12):1021-30. PubMed ID: 23861168
[TBL] [Abstract][Full Text] [Related]
16. GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production.
Miller C; Pachanski MJ; Kirkland ME; Kosinski DT; Mane J; Bunzel M; Cao J; Souza S; Thomas-Fowlkes B; Di Salvo J; Weinglass AB; Li X; Myers RW; Knagge K; Carrington PE; Hagmann WK; Trujillo ME
PLoS One; 2017; 12(5):e0176182. PubMed ID: 28542610
[TBL] [Abstract][Full Text] [Related]
17. Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice.
Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M
Biochem Biophys Res Commun; 2010 Nov; 402(2):280-5. PubMed ID: 20937249
[TBL] [Abstract][Full Text] [Related]
18. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Toda N
Bioorg Med Chem Lett; 2014 Jul; 24(13):2949-53. PubMed ID: 24835985
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
